Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.
about
Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect.Identification of a new peptide for fibrosarcoma tumor targeting and imaging in vivoA Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in MiceRenal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient miceDosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Affibody-mediated PET imaging of HER3 expression in malignant tumours.Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphyThe joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursRadioiodine-induced kidney damage and protective effect of amifostine: An experimental study.Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotateProspects in folate receptor-targeted radionuclide therapyMolecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Lutetium-labelled peptides for therapy of neuroendocrine tumours.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity.The role of patient-based treatment planning in peptide receptor radionuclide therapy.Adverse events in nuclear medicine - cause for concern?The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Borderline Low and Discordant Renal Parameters: Treatment Feasibility Assessment by Sequential Estimation of Triple Parameters and Filtration Fraction.Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis.Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q33686825-6588AAC2-CFD2-407C-8B0C-46679BCAE951Q33769196-6D6029AC-9F23-4584-8F25-F8B5E6CBB2ADQ33851549-2DF07C1B-6729-4BC3-B82B-903940BEFA1AQ34647984-7FE0CF73-FAB6-4312-AB1A-1FFA66DB5D40Q35402008-00C66838-B95D-4815-94EC-88F41E261007Q36157472-D86EB689-C125-4B7A-B2F6-2F5112CE6370Q36174716-13428C0F-3029-439E-B183-B78741BB63EBQ36423806-50622D43-2349-4B07-97AB-1246DE48BF7FQ36755905-41B40E3A-9A87-4F55-B308-E141E46D4C4AQ37082662-61C0D6DA-C67B-45E6-8B45-CABA0914499AQ37143853-BDC811BD-9C26-4136-A7B9-A5C73EDBE90DQ37193061-3D0459B3-D8E0-4B3C-9078-F3ED9A2D75E3Q37763924-9DD7BF4B-91BB-469C-9B47-0C0264AA5156Q37975101-4022C484-482F-4006-9A94-5EAC9D07B028Q37990411-1A1EC753-BEC0-44F0-B877-C90F4704B767Q38008839-3407680F-DC8B-4B60-A741-9C0A777EC7E1Q39338039-7265E278-3A7F-4FA6-84FE-7BEE5EE80480Q39373913-220A8017-147E-48CF-86AE-732A70A1DDEEQ39430065-F133C2BD-826D-4598-8D93-49B617C4C1D2Q39447268-F8B3B0D2-33A5-4854-92C4-106428E1CA07Q40311407-D5CF03FA-F0B4-4D83-BBA5-74D9B973B812Q45460559-4F3F588B-612D-4662-A96D-FD35A198DE28Q47730141-FD3CC481-C950-4228-BA04-4B59E28BC557Q47988504-6696660E-BB63-4A2E-AF9D-89C92DAAAB45Q49176798-5CE8FB3C-DE73-4C42-9D6C-27EA85B7C377Q52682131-6FB95F70-EC8F-4B28-BFBE-B0375D0DA74EQ55269808-67B5264D-5808-4F43-B785-C8ACC0DBA6EDQ57990732-0A74D826-26D1-4AE6-A9B5-4D6981A2E8C3
P2860
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Kidney protection during pepti ...... y with somatostatin analogues.
@en
Kidney protection during pepti ...... y with somatostatin analogues.
@nl
type
label
Kidney protection during pepti ...... y with somatostatin analogues.
@en
Kidney protection during pepti ...... y with somatostatin analogues.
@nl
prefLabel
Kidney protection during pepti ...... y with somatostatin analogues.
@en
Kidney protection during pepti ...... y with somatostatin analogues.
@nl
P2093
P2860
P1476
Kidney protection during pepti ...... y with somatostatin analogues.
@en
P2093
Edgar J Rolleman
Eric P Krenning
Marion de Jong
Marleen Melis
Roelf Valkema
P2860
P2888
P304
P356
10.1007/S00259-009-1282-Y
P577
2009-11-14T00:00:00Z